505(b) (2) application is one of the advantageous ways of regulatory submission. This submission approach can lead to fast-track approval for wide-ranging products, exclusively for those that exemplify a limited change from formerly approved drug. Safety and efficacy evidence in terms of non-clinical and clinical portion of the Reference Listed Drug (RLD), are trusted upon. Additionally, supplementary data essentially required to establish comparability with the RLD, are presented in the dossier.
Methods
This retrospective analysis is to understand the FDA's expectations and avoid errors in terms of data support approval for a new product submitted under the 505 (b) (2) route. The current script is an analysis on how to architect 505(b) (2) regulatory strategy by developing a different set of documents/information.
Results
The ultimate goal of this review is to allow drug developers to easily navigate through various 505 (b) (2) submissions and defense strategies for registration processes available to the new drug manufacturers and to understand an effective, safer filing route by facilitating early market launch with a prospect of lower cost.
Conclusion
Before considering option 505 (b) (2), general companies should have a good understanding of product’s potential productivity, scalability, patent infringement, expensive clinical studies and/or non-clinical studies to appropriately strategize scientific and commercial opportunities. This leverage will potentially quicken the development program and will definitely lower the clinical and regulatory risk of new product entrants.
PrasadCPrabodhMAshishS, et al. Concept of 505 (b)(2) application: Benefits and challenges. Int J Drug Regul Aff2014; 2: 16–20.
5.
FreijeILamoucheSTanguayM.Review of drugs approved via the 505(b)(2) pathway: Uncovering drug development trends and regulatory requirements. Ther Innov Regul Sci2020; 54: 128–138.
6.
KumarMJethwaniH.The 505 (b)(2) drug development pathway : When and how to take advantage of a Unique American Regulatory Pathway. Regul Focus2010; 505: 9–13.
7.
DuggalE, Kashyap P, Singh R, et al. Fast track approaches for drug approval across the globe. Asian Pacific Journal of Health Sciences 2014; 1: 2–12.
Midatech chief talks Zuplenz launch and 2015 sales beat, Proactive Investors Australia; Video Release Available at: https://www.youtube.com/watch?v=EWiU5F4i-FE [Accessed on 6th January 2020].
Nadler HL, DeGraft-Johnson D. Demystifying FDA’s 505(b)(2) Drug Registration Process. Regulatory Focus, 2009, 1-7, Available at http://djaglobalpharma.com/Demystifying_FDA.pdf (Accessed on 15th October 2020)
17.
US FDA, CDER. Guidance for industry: applications covered by section 505 (b) (2). Available from: https://www.fda.gov/media/72419/download [Accessed 20th August 2020].
18.
Prasad V, Biswas M, Vishal S. Is 505 (b)(2) filing a safer strategy: avoiding a known risk?. International Journal of Intellectual Property Management. 2014; 7(1-2): 1-14.
